Drug Trial Radar · NCT04650854
A Study to Evaluate Rozanolixizumab in Study Participants With Generalized Myasthenia Gravis
Last checked: Nov 20, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
165
Actual
Start
Feb 3, 2021
Primary completion
Jan 25, 2024
Study completion Jan 25, 2024
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Dec 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the safety, tolerability and efficacy of additional 6-week treatment cycles with rozanolixizumab in study participants with generalized myasthenia gravis (gMG).
Conditions
- Generalized Myasthenia Gravis
Interventions
RozanolixizumabDrug
Rozanolixizumab will be administered by subcutaneous infusion in dosage regimen 1 or 2.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: From Baseline (Day 1) to End of Study (up to 34 months)
- Percentage of Participants With TEAEs Leading to Withdrawal of Investigational Medicinal Product (IMP)Time frame: From Baseline (Day 1) to End of Study (up to 34 months)
Locations
69 sites in 14 countries. Site status is shown where the registry gives one.
Mg0007 50092
Orange, California
Mg0007 50099
San Francisco, California
Mg0007 50122
Miami, Florida
Mg0007 50120
Miami, Florida
Mg0007 50073
Tampa, Florida
Mg0007 50075
Augusta, Georgia
Mg0007 50323
Honolulu, Hawaii
Mg0007 50114
Indianapolis, Indiana
Mg0007 50121
Lexington, Kentucky
Mg0007 50077
New York, New York
Mg0007 50090
Winston-Salem, North Carolina
Mg0007 50096
Philadelphia, Pennsylvania
Mg0007 50113
Houston, Texas
Mg0007 50071
Edmonton, Canada
Mg0007 50066
Montreal, Canada
Mg0007 50124
Montreal, Canada
Mg0007 50070
Québec, Canada
Mg0007 50069
Toronto, Canada
Mg0007 40125
Ostrava - Poruba, Czechia
Mg0007 40124
Prague, Czechia
Mg0007 40128
Aalborg, Denmark
Mg0007 40127
Aarhus, Denmark
Mg0007 40126
Copenhagen, Denmark
Mg0007 40129
Bordeaux, France
Mg0007 40360
Limoges, France
Mg0007 40132
Nice, France
Mg0007 40133
Paris, France
Mg0007 40131
Strasbourg, France
Mg0007 20160
Tbilisi, Georgia
Mg0007 20161
Tbilisi, Georgia
Mg0007 20163
Tbilisi, Georgia
Mg0007 20164
Tbilisi, Georgia
Mg0007 20165
Tbilisi, Georgia
Mg0007 40134
Essen, Germany
Mg0007 40140
Göttingen, Germany
Mg0007 40139
Jena, Germany
Mg0007 40078
Leipzig, Germany
Mg0007 40177
Münster, Germany
Mg0007 40283
Bologna, Italy
Mg0007 40144
Milan, Italy
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.